Insilico Medicine announced ISM5059, a peripheral‑restricted NLRP3 inhibitor, as its nominated preclinical candidate and highlighted its presence at WHX 2026 to showcase partnerships bridging the Middle East and global translational research. The small‑molecule nomination underscores the company’s AI‑driven drug design pipeline and movement from in‑silico discovery toward in‑vivo validation. Insilico’s communications emphasize AI as an industrialized discovery engine and the company’s strategy to partner internationally to accelerate preclinical and translational development. The ISM5059 selection spotlights AI’s role in generating chemically tractable candidates against difficult innate‑immune targets.